

Phosphate

PRESENTATION:

Addiphos® 20ml vials containing phosphate 40mmol, potassium 30mmol and sodium 30mmol

Potassium acid phosphate 10ml ampoules containing phosphate 10mmol (1mmol/ml) and potassium 10mmol (1mmol/ml). (WGH and RIE only)

Sodium glycerophosphate 20ml ampoules containing phosphate 20mmol (1mmol/ml) and sodium 40mmol (2mmol/ml) (WGH and RIE only)

Phosphate 500ml polyfusor containing phosphate 50mmol, potassium 9.5mmol and sodium 81mmol

INDICATION:

Hypophosphataemia

DOSE AND ADMINISTRATION: ICU STANDARD INTRAVENOUS INFUSION

Addiphos® 20ml made up to 60ml with glucose 5% over 6 hours centrally, or 20ml Addiphos® in 500ml glucose 5% over 6 hours peripherally.

A 500ml phosphate polyfusor can be given centrally or peripherally over 12 hours.

If hypernatraemia a concern consider:

Potassium acid phosphate (1mmol/ml) 40ml made up to 60ml with glucose 5% over 6 hours centrally.

If hyperkalaemia a concern consider:

Sodium glycerophosphate (phosphate 1mmol/ml, sodium 2mmol/ml) 40ml made up to 60ml with glucose 5% over 6 hours centrally.

STABILITY:

Physically and chemically stable for 24 hours at room temperature

ADDITIONAL NOTES:

A phosphate polyfusor may be given over 6 hours if necessary.

References:

1. Addiphos®. Fresenius Kabi. Summary of Product Characteristics. 02/2009. Accessed 10/8/18 (Revision of text 25/5/16)
2. Phosphates Polyfusor®, Fresenius Kabi. Summary of Product Characteristics. 02/2009. Accessed 10/8/18 (Revision of text 20/10/14)
3. Sodium glycerophosphate. Fresenius Kabi. Summary of Product Characteristics. 02/2009. Accessed 10/8/18 (Revision of text 02/11/16)
4. Potassium Acid Phosphate Solution 13.6%. Martindale Pharmaceuticals. Summary of Product Characteristics. 02/2015. Accessed 10/8/18 (Revision of text 11/99)
5. Personal communication with Fresenius-Kabi and Martindale Medicines Information regarding stability of products. 08/2018.

Title: Phosphate	
ID:	Authors: Hannah Prescott
Category:	Document Version: 2.0
Status Draft/Final: FINAL	Review Date: December 2021
Authoriser:	Authorisation Date: March 2019
Date added to Intranet	
Key Words	
Comments	